Christopher Hourigan
Christopher Hourigan | |
|---|---|
| Alma mater | Oxford University |
| Known for | Acute Myeloid Leukemia and Measurable Residual Disease |
| Awards | Alpha Omega Alpha, Johns Hopkins Chapter Honorary Fellow, Royal College of Physicians, NHLBI Directors Award NHLBI Orloff Award NIH Bench to Bedside Award NIH Directors Challenge Innovation Award American College of Physicians Early Career Physician Award American Society for Clinical Investigation Young Physician-Scientist Award Presidential Early Career Award for Scientists and Engineers (2019) |
| Scientific career | |
| Institutions | National Institutes of Health |
| Website | https://www.nhlbi.nih.gov/science/myeloid-malignancies |
Christopher Hourigan is a physician-scientist known for work on measurable residual disease (MRD; previously termed minimal residual disease) in acute myeloid leukemia.
He was previously Chief of the Laboratory of Myeloid Malignancies at the National Heart, Lung, and Blood Institute and founding co-director of the Myeloid Malignancies Program at the National Institutes of Health in Bethesda, Maryland.